The progress of interleukin-33 on liver diseases
10.3760/cma.j.issn.1007-8118.2019.09.021
- VernacularTitle: 白细胞介素33及其在肝脏疾病中作用的研究进展
- Author:
Jie ZHANG
1
;
Feng ZHANG
2
;
Chuanqing BAO
3
Author Information
1. Medical College of Nantong University, Nantong 226001, China
2. Institute of Integrative Medicine, Affiliated Hospital of Jiangnan University, Wuxi 214000, China
3. General Surgery, Affiliated Hospital of Jiangnan University, Wuxi 21400, China
- Publication Type:Review
- Keywords:
Interleukin-33;
ST2;
Liver disease
- From:
Chinese Journal of Hepatobiliary Surgery
2019;25(9):715-720
- CountryChina
- Language:Chinese
-
Abstract:
Interleukin-33 (IL-33) is a multifunctional gene in the interleukin-1 family and is widely expressed in human tissues. Its receptor is ST2, is associated with asthma, diabetes, Alzheimer's disease, cardiovascular disease, inflammatory bowel disease, and cancer. IL-33, enhancing lipid metabolism and down-regulating adipogenic gene expression by inducing Th2 cytokine production, plays a protective role in fatty liver. In hepatitis, the IL-33/NKT/IFN-γ pathway exacerbates mouse hepatitis. While, the IL-33/ILC2/IL-13/STAT6 pathway reduces liver damage. The IL-33/ILC2/IL-13/IL-4Rα/STAT6 axis plays a facilitating role in cirrhosis. In liver cancer, IL-33/ILC2/IL-13 signaling pathway is found to promote cholangiocarcinoma in a favorable pathological environment, and hepatocellular carcinoma occurs by IL-33/IL-6/JAK/STAT/Mcl-1 signaling pathway.
